John D. Quisel Sells 13,012 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 13,012 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $61.95, for a total transaction of $806,093.40. Following the completion of the transaction, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,464,426.75. This trade represents a 15.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Disc Medicine Stock Performance

NASDAQ IRON opened at $63.82 on Friday. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60. The business has a 50 day simple moving average of $61.89 and a 200 day simple moving average of $52.19. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -16.04 and a beta of 0.75.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15. On average, analysts predict that Disc Medicine, Inc. will post -4.05 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IRON. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a report on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Wedbush restated an “outperform” rating and issued a $83.00 price target on shares of Disc Medicine in a research report on Monday, December 9th. Jefferies Financial Group started coverage on Disc Medicine in a research note on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a research report on Monday, December 9th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine presently has a consensus rating of “Buy” and an average price target of $87.50.

Institutional Trading of Disc Medicine

A number of institutional investors have recently modified their holdings of IRON. Amalgamated Bank raised its holdings in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after buying an additional 337 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Disc Medicine by 2.7% during the third quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock worth $1,428,000 after acquiring an additional 771 shares in the last quarter. SG Americas Securities LLC lifted its stake in Disc Medicine by 19.5% in the third quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock valued at $239,000 after acquiring an additional 793 shares during the last quarter. Finally, TD Asset Management Inc grew its position in shares of Disc Medicine by 3.7% in the 2nd quarter. TD Asset Management Inc now owns 40,732 shares of the company’s stock valued at $1,836,000 after acquiring an additional 1,468 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.